The study is to investigate drug-drug interaction ( DDI ) between olmesartan medoxomil and hydrochlorothiazide ( HCTZ ) , to confirm bioequivalence ( BE ) of a new combined formulation and coadministration of separate local tablets , and to receive pharmacokinetics and tolerability of the new combined formulation after multiple doses in healthy Chinese subjects .